Verification evidence is still being completed.
PDF / print export
CureVac
Tübingen, Germany
- Verified lead
- Alexander Zehnder
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- mRNA Therapeutics, Translational Development, and RNA Platform Operations
- Review cycle
- May 2026
- Full address
- Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official CureVac management page confirming Alexander Zehnder as CEO.
- Editorial note
- CureVac adds a German mRNA platform node relevant to the cluster's biologics and vaccine-development intelligence layer.
mRNA Therapeutics, Translational Development, and RNA Platform Operations
Clinical-stage mRNA quality systems, Regulated development platform
CureVac adds a German mRNA platform node relevant to the cluster's biologics and vaccine-development intelligence layer.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Tübingen, Germany
CureVac
mRNA Therapeutics, Translational Development, and RNA Platform Operations · Clinical and translational development
Verified 14 Mar 2026 · 3 sources
BiologicsmRNAVaccineClinical
CureVac adds a German mRNA platform node relevant to the cluster's biologics and vaccine-development intelligence layer.
Contact & location
- Website
- curevac.com
- [email protected]
- Company page
- Lead
- Alexander Zehnder (verified ↗)
- Compliance
- GMP · GLP
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Clinical and translational development
- Capabilities
- mRNA Platform Development · Clinical Translation · RNA Therapeutic Operations
- Founded
- 2000
- Headcount
- 1001-5000
Clinical profileSTATUS: VERIFIED MARCH 2026
Alexander Zehnder
Chief Executive Officer
Full addressFriedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Official CureVac annual report naming the principal executive offices at Friedrich-Miescher-Strasse 15 in Tuebingen.
Open sourceClinical and translational development
Tübingen, Germany. mRNA Therapeutics, Translational Development, and RNA Platform Operations. Review completed on 14 Mar 2026.
German and EU medicinal product oversight
Clinical-stage mRNA quality systems, Regulated development platform
mRNA Therapeutics, Translational Development, and RNA Platform Operations
CureVac adds a German mRNA platform node relevant to the cluster's biologics and vaccine-development intelligence layer.
Editorial note
CureVac adds a German mRNA platform node relevant to the cluster's biologics and vaccine-development intelligence layer.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
mRNA Platform Development
Clinical Translation
RNA Therapeutic Operations
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
RNA platform laboratories
Development analytics
Translational process systems
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is CureVac located?
- CureVac operates from Friedrich-Miescher-Strasse 15, 72076 Tuebingen, Germany, Tübingen, Germany.
- Who runs CureVac?
- CureVac is led by Alexander Zehnder, Chief Executive Officer. Verified 14 Mar 2026.
- What does CureVac do?
- CureVac adds a German mRNA platform node relevant to the cluster's biologics and vaccine-development intelligence layer. Core capabilities: mRNA Platform Development, Clinical Translation, RNA Therapeutic Operations.
Editorial context
Related technical briefs
Briefs that name Tübingen as a covered market or city.